Drug
BI 695500
BI 695500 is a pharmaceutical drug with 4 clinical trials. Historical success rate of 25.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
25.0%
Based on 1 completed trials
Completion Rate
25%(1/4)
Active Trials
0(0%)
Results Posted
400%(4 trials)
Terminated
3(75%)
Phase Distribution
Ph phase_3
3
75%
Ph phase_1
1
25%
Phase Distribution
1
Early Stage
0
Mid Stage
3
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 3Large-scale testing
3(75.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
25.0%
1 of 4 finished
Non-Completion Rate
75.0%
3 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(1)
Terminated(3)
Detailed Status
Terminated3
Completed1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
25.0%
Most Advanced
Phase 3
Trials by Phase
Phase 11 (25.0%)
Phase 33 (75.0%)
Trials by Status
completed125%
terminated375%
Recent Activity
0 active trials
Showing 4 of 4
completedphase_1
Pharmacokinetics and Pharmacodynamics of BI 695500 vs. Rituximab as First Line-treatment in Patients With Low Tumor Burden Follicular Lymphoma
NCT01950273
terminatedphase_3
Efficacy, Pharmacokinetics, and Safety of BI 695500 in Patients With Rheumatoid Arthritis
NCT01682512
terminatedphase_3
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis
NCT01955733
terminatedphase_3
BI 695500 vs Rituxan First Line Treatment in Patients With Low Tumor Burden Follicular Lymphoma
NCT02417129
Clinical Trials (4)
Showing 4 of 4 trials
NCT01950273Phase 1
Pharmacokinetics and Pharmacodynamics of BI 695500 vs. Rituximab as First Line-treatment in Patients With Low Tumor Burden Follicular Lymphoma
NCT01682512Phase 3
Efficacy, Pharmacokinetics, and Safety of BI 695500 in Patients With Rheumatoid Arthritis
NCT01955733Phase 3
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis
NCT02417129Phase 3
BI 695500 vs Rituxan First Line Treatment in Patients With Low Tumor Burden Follicular Lymphoma
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4